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Abstract
We systematically searched published empirical research on depression and cardiovascular disease
(CVD) and found 494 unique articles published in 2009. Herein, we present selected provocative
findings or interesting controversies, and, where appropriate, we discuss the clinical implications
of these findings.
In 2009, there were many scientific advances in understanding the relationship between
depression and CVD. As the study of this phenomenon encompasses the fields of
cardiology, psychiatry, behavioral medicine, as well as many others, it is difficult to keep
abreast of new developments. Relevant papers may be found in a variety of journals.
Therefore, we used a systematic search strategy to retrieve the most relevant articles about
depression and coronary heart disease (CHD) from the MEDLINE and PsycINFO (Ovid
interface) databases. The most relevant subject headings and free text terms were identified
and combined with “or.” The 2 sets were then combined with “and.” Terms included
“depression,” “depressive disorder,” “depress$,” “coronary artery disease” (CAD) “coronary
disease,” “acute coronary syndrome” (ACS), “cardiovascular disease” (CVD), “coronary
heart disease,” and “heart diseas$.” The final set was limited to the English-language
literature and identified almost 500 articles published during 2009. Closer inspection of titles
and abstracts revealed well over 100 articles that were directly relevant to the science and
management of patients with CVD and depression or pronounced depressive symptoms.
Therefore, a thorough review of all new findings, editorials, and reviews is not feasible.
Herein, we present a few of the many exciting or potentially influential articles published in
2009 that could affect the views of the relationship between depression and CVD, and how
we screen or treat depression in patients with CVD. As with any review that is not evidenced
based, our choice of articles is subjective and is incomplete, but we hope it will serve as a
stimulus for discussion and further exploration.
Previous evidence demonstrated that depressive symptoms as well as a diagnosis of a
depressive disorder predict poor prognosis and reduced survival rates after any CAD
diagnosis, including myocardial infarction (MI) and unstable angina, as well as after
coronary artery bypass graft (CABG) surgery.1 Investigations in 2009 focused on better
understanding outcomes, the type of depression implicated in this association, and the risks
and benefits of antidepressant use, psychotherapy, and omega-3 fatty acid supplementation.
We start by reviewing the recent observational literature on antidepressant use and clinical
outcomes.
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Observational Evidence on Antidepressant Use and CVD Outcomes
An analysis of the Nurses' Health Study conducted by Whang et al2 examined depressive
symptoms and antidepressant use in 63 469 women without CVD using the Mental Health
Index, a 5-item subscale of the Short Form-36 Health Survey, and their relationship to
sudden cardiac death and adverse cardiac events. Most women who reported antidepressant
use (61%) were taking a selective serotonin reuptake inhibitor (SSRI; sertraline, fluoxetine,
paroxetine, or citalopram), while 39% reported other antidepressant use. Women taking
antidepressants were more likely to have sudden cardiac death. The fully adjusted hazard
ratio (HR) for sudden cardiac death in women taking antidepressants was 3.34 (95%
confidence interval [CI], 2.03–5.50).
A study by Krantz et al3 examined psychotropic medication use and risk of adverse
cardiovascular events in 519 women from the Women's Ischemia Syndrome Evaluation
(WISE) study. Enrolled women underwent coronary angiography, were separated into 4
groups according to their psychotropic medication use (no medication, anxiolytics only,
antidepressants only, and a combination of anxiolytics and antidepressants), and were
observed for a median of 5.9 years. Results revealed that women who received both
medications had a higher risk for adverse cardiovascular events as well as all-cause
mortality compared with those using neither medication, even when controlling for anxious
and depressive symptoms. In addition, while the use of antidepressant medication was
associated with a doubling of risk for subsequent CVD events (hazard ratio, 2.16; 95% CI,
1.21–3.93) and all-cause mortality (hazard ratio, 2.15; 95% CI, 1.16–3.98), use of anxiolytic
medication alone was not.3 There was no investigation in this study of cause of death,
although in this cohort selected for likelihood of coronary artery disease, cardiac death is
likely to have comprised a large proportion of total mortality.
Although CVD and death have long been outcomes of interest for those studying
depression's effect, some other end points have recently been investigated. Smoller et al4
found that new antidepressant use was significantly associated with increased incidence of
stroke and all-cause mortality, but it was not associated with incidence of CHD in a
prospective cohort study of 136293 community-dwelling postmenopausal women in the
Women's Health Initiative (WHI) study. For subjects with no antidepressant use and SSRI
use, the reported annualized rates per 1000 person-years were 2.99 and 4.16, respectively,
for stroke and 7.79 and 12.77, respectively, for all-cause mortality. The annualized death
rate for subjects taking new tricyclic antidepressant medication was 14.14 per 1000 person-
years. To address potential confounding by indication, Smoller et al obtained a propensity
score from a logistic regression model to predict any new antidepressant use from
demographic, lifestyle, risk factor, and comorbidity variables measured at baseline. New
SSRI use was associated with a doubling of the risk of incident hemorrhagic stroke as well
as fatal stroke. There were no significant interactions between use of SSRIs and use of
statins or aspirin for the risk of hemorrhagic stroke.
In an interesting observational study of 7709 patients with confirmed CAD5 but without a
diagnosis of heart failure, or of depression, or current use of antidepressants, a subsequent
diagnosis of depression was associated with a significant 50% increased risk of heart failure.
However, there was no difference between depressed patients who were using
antidepressants and those who were not.
Increased risk of bleeding with SSRI use, particularly in patients with CAD, has also been a
concern. Kim et al6 evaluated 1380 adults who received any antidepressant before CABG
for in-hospital mortality or any bleeding events. After controlling for the percentage of
patients taking SSRIs (78%) there were no significant differences between those taking
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SSRIs and those who were not in any bleeding events (6.5% vs 7.2%; odds ratio, 0.93; 95%
CI, 0.50–1.76) or in-hospital mortality (3.1% vs 2.3%; odds ratio, 0.88; 95% CI, 0.47–1.65).
There was no increased risk of bleeding associated with SSRI use when the analysis was
restricted to patients who received antiplatelet and anticoagulant therapy. Thus, compared
with patients who were not taking SSRIs, the preoperative use of SSRIs did not increase the
risk for bleeding or in-hospital mortality after CABG; however, this study did not evaluate
the effect of no antidepressant use.
Another study hypothesized that use of any drug with the potential to prolong cardiac
repolarization would be associated with an increased risk of sudden death.7 Among 1010
cases (sudden unexplained death) and 3030 living primary care controls all from the
community, risks for individual drugs were tested.7 SSRI use was associated with a
doubling of sudden death risk (odds ratio 2.21; %95 CI 1.61, 3.05) and a non-significant
trend was noted among users of tricyclic antidepressants (odds ratio= 1.44; %95 CI 0.96,
2.13). When the analysis was re-analyzed to stratify on prior CVD, most of this SSRI
sudden death risk was in those with existing CVD, and not in those without CVD. Other
drugs found to raise sudden death risk included the typical and atypical antipsychotics.
Summary and Clinical Implications for Antidepressant Use in Patients With
CVD
The analysis by Whang and colleagues2 of the Nurses' Health Study suggested a tripling of
the risk of sudden cardiac death for healthy women who take antidepressant medication, and
the authors suggested that the association between fatal ventricular arrhythmias and
antidepressant use should be examined further. The analysis by Smoller et al4 of the WHI
study found that use of SSRIs and tricyclic antidepressants doubled the risk of fatal stroke in
healthy women. The analysis by Krantz et al3 of the WISE study found a doubling of the
risk of CVD and death in women taking antidepressants who had been referred for coronary
angiography. May et al5 did not find that antidepressant use increased the risk for heart
failure conversion in patients with CAD, and Kim et al6 did not find an increased risk of
bleeding in patients with CAD undergoing CABG when SSRI use was compared with non-
SSRI antidepressant use. Finally, in a population- and community-based case-control study,
SSRI use was associated with an increased risk of sudden death, particularly in patients with
CHD.7 So what are we to make of these findings?8
With all observational studies (including those reviewed above), unmeasured confounders
pose a threat to the validity of any causal conclusions. A study recently tested some of the
proposed confounders that might have existed in the above studies. Waldman et al9
examined racial differences in depressive symptoms and antidepressant treatment in a cohort
of 864 consecutive patients with CHD undergoing diagnostic coronary angiography (727
white and 137 African American patients). While both whites and African Americans had
similar levels of depression, African Americans with CHD were less likely than their white
counterparts to receive antidepressant medications. In fact, those undergoing CABG and
African Americans were the only two groups who were significantly less likely to receive a
prescription for antidepressants. Patients with a only some high school, men, and patients
with more severe depressive symptoms were significantly more likely to receive a
prescription for antidepressants.9 Clearly, many of these variables are related to poor
prognosis for CHD, and the simple interpretation that antidepressant use is causing poorer
outcomes is problematic.8
Two additional interpretations of the observational findings should be considered. First,
confounding by indication (depressive symptom severity) might exist in these studies.10
That is, patients who are prescribed antidepressant medication may be those with the most
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severe depressive illness, and it could be this severity, rather than the antidepressant use, that
is causally implicated in the risk of CVD incidence.11 However, all of the studies reviewed
above either directly controlled for depressive symptom severity (at least as obtained at
baseline) or used propensity scores or stratified subjects based on depression severity. The
results showed an increased risk for those who were taking antidepressants. However, none
of the studies examined depressive symptom severity during or at the end of the study or
depression diagnosis and severity before antidepressant use; these data are needed to more
clearly understand if the results were confounded by indication.
Second, these findings are also consistent with a treatment-resistant depression phenotype.12
Krantz and others3 caution that it is not clear from their observational study if medication
use itself or depression refractory to treatment is implicated in the increased risk of CVD
events and mortality. Depression that is refractory to treatment may be the type of
depression that places patients at risk for sudden death, stroke, or CHD recurrence, and thus
it may not be the antidepressant use per se that is associated with this risk. This phenomenon
had been documented in a secondary analysis13 of the largest-to-date randomized controlled
trial of patients with MI undergoing treatment for depression (ENRICHD).14 The results
showed that those whose depression symptoms did not respond to treatment had a higher
risk of late mortality (ie, death occurring ≥6 months after acute MI). This finding was
replicated in 2009 in an important follow-up15 of the SADHART trial;16 patients with MI
and major depression, treatment-resistant depression (ie, depression that failed to improve
substantially during treatment with either sertraline or placebo) was strongly and
independently associated with long-term mortality (hazard ratio, 2.39; 95% CI, 1.39–2.44; P
< .001).
What is needed next? To test the alternative hypothesis that an unmeasured confounder may
exist is difficult. It requires conducting new observational studies and measuring the putative
third common causes or previously unmeasured confounder. Other putative confounders will
then be hypothesized and will need to be included in additional observational studies. To
properly test the putative confounding by depressive symptom severity, future observational
studies should examine initial depressive symptom severity prior to antidepressant use and
then collect depressive symptom severity and antidepressant use as time-varying covariates
to CVD outcomes. To test if treatment-resistant depression is the phenotype driving the
spurious observational association between antidepressant use and increased risk of CVD,
the phenotype and its underlying causal mechanisms need to be better understood. Of
course, adequately powered, rigorous, randomized controlled trials of antidepressant use in
patients with CVD would be a more straightforward way to test the observational
association between antidepressant use and increased risk of CVD. We turn now to the
recently published randomized controlled trials in this field.
New Evidence From Randomized Controlled Trials in Patients With CVD
and Depression
Concerns have been voiced for some time about the ability to effectively treat depression
and whether an effective depression treatment will affect the risk of CVD recurrence and
mortality.8 Adding to these concerns is that we know little about the causal pathways and
behavioral and biological mechanisms implicated in this risk association.1 For these reasons,
results from new randomized controlled trials, such as the 4 summarized below, are
important. Rollman and others17 tested the effectiveness of telephone-delivered
collaborative care (treatment group) vs usual physician care (control group) for improving
mental health quality of life and reducing depressive symptoms in patients with depression
after CABG. Patients with depression after CABG (N=302) were randomized to either the
treatment or control group and observed for 8 months; mental health quality of life and
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depressive symptoms were significantly improved in the treatment vs control group.
Significantly more patients in the treatment group had a 50% or greater reduction in
depression symptoms compared with usual care patients (P <.001; 50.0% vs 29.6%; number
needed to treat, 4.9 [95% CI, 3.2–10.4]). Men particularly benefited from the treatment. This
trial suggests that collaborative care can be effectively (and potentially cost-efficiently)
delivered over the phone.
Freedland and others18 also tested depression treatment in 123 patients with major or minor
depression who underwent CABG. The primary purpose of the trial was to determine the
efficacy of 2 behavioral treatments (cognitive behavioral therapy or supportive stress
management) compared with usual care. Significantly more patients in the depression
treatment group (71%) and the stress treatment group (57%) had a low score on the
clinician-based Hamilton rating scale compared with the usual care group (33%). These
results were maintained 6 months after the end of the trial. Secondary measures of
depressive symptoms, anxiety, and quality of life were also significantly improved in the
depression treatment group compared with the usual care group. This trial is important for
the following reasons: (1) The use of a second control group, the stress management group,
is a strict, high-quality design that controls for professional attention, generic or placebo
therapy effect, and time or effort on the part of the patient. (2) The second control group also
provides treatment options for the patient because both cognitive behavioral therapy and
stress management were beneficial. (3) Second outcome assessors were blinded to treatment
assignment, an important design feature in behavioral trials.
In a rigorously conducted randomized double-blind placebo-controlled trial, Carney and
others19 tested if omega-3 acid ethyl esters (2 g; combined EPA and DHA) improved
depressive symptoms in 122 patients with major depression and CHD. Patients in both the
omega-3 and placebo groups received sertraline (50 mg) during the 10-week trial. A
deficiency of omega-3 has been implicated in both depression and CHD and was a possible
causal link between the 2 diseases. Also, there is some evidence that the efficacy of
antidepressants is increased when an omega-3 fatty acid supplement is added. Unfortunately,
there were no differences in self-reported or clinician-based depressive symptoms or in
predefined depression remission at trial end The trial added a 2-week adherence run-in
period, ensuring that medication adherence in the trial was excellent (97%) and concluded
that, at least at these dosage levels, omega-3 does not improve depression outcomes.
Davidson et al20 conducted the Coronary Psychosocial Evaluation Studies (COPES)
randomized controlled trial including 157 patients with ACS and persistently elevated
depressive symptoms in which a patient-preference, stepped depression (enhanced care)
algorithm was compared with usual care for 6 months. The purpose of the trial was to
determine acceptability and efficacy of depression treatment among patients with ACS, who
often neither agree with the diagnosis of depression nor sought treatment for depression. At
the beginning of treatment, patients received either problem-solving therapy or
antidepressant medication, depending on their choice, with the option of later augmentation
with the other treatment. Significantly more patients were satisfied with their depression
care in the treatment arm, and depressive symptoms and major adverse cardiac events
(nonfatal MI, hospitalization for unstable angina, or all-cause mortality) were significantly
reduced compared with the usual care arm. The absolute numbers were very small; at the
end of the trial, 3 patients in the intervention group and 10 patients in the usual care group
had major adverse cardiac events (4% and 13%, respectively; log-rank test, χ21=3.93; P=.
047). The results suggested that involving patients in the type of depression care (medication
and/or psychotherapy) they receive and stepping treatments aggressively may be methods to
improve the treatment of depression in patients with CVD. In addition, persistently
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depressed patients may be an interesting patient group to select for future trials; usual care
has resulted in large reductions in depressive symptoms in some previous trials.
Summary and Clinical Implications for Recent Randomized Controlled
Trials in Patients With CVD and Depression
Each of these 4 efficacy trials adds critical information to the evidence base. Depressed
patients who have undergone CABG can be effectively treated in primary care settings with
integrative care, and cognitive behavioral therapy for these patients is also extremely
effective. Additional studies of omega-3 supplements should not be pursued at this time, but
using a run-in period to better identify patients who are prepared to engage in treatment is a
prudent idea and should be used in future trials in this area. Patients with CHD and
persistent depressive symptoms are a promising group to target for depression treatment.
Asking patients to choose the type of depression treatment may improve the response to
treatment for both depression and CVD.
Depression Screening, Referral, and Treatment in Patients With CVD
We finish with the least evidence-based and most controversial issue in the area of
depression and CVD. This controversy started in 2008 when the American Heart
Association recommended (and the American Psychiatric Association endorsed)21 that
“screening tests for depressive symptoms should be applied to identify patients who may
require further assessment and treatment” if appropriate referral for further depression
assessment and treatment is available. Partly in response to this advisory, Thombs et al22
conducted a systematic review of the evidence that screening or treatment improves
outcomes of depression or CVD in patients with CVD. They found no trial that tested if
depression screening was beneficial in patients with CVD, and the randomized controlled
trials of depression treatment provided evidence of only mild improvement of depression
symptoms and no improvement in CVD outcome. Therefore, they questioned whether
routine depression screening was appropriate.
In at least 7 editorials and reviews published in 2009, authors continued to debate this issue.
23–30 Below, we provide a simplified list of reasons presented for and against screening and
subsequent treatment raised in these articles.
Arguments for Depression Screening, Referral, and Treatment in Patients
With CVD
The proponents for screening stated that depression is highly prevalent in CVD patient
populations and is clearly a risk marker for increased adverse events as well as decreased
quality of life and adherence to treatment.24 As there are plausible biological and behavioral
mechanisms for this association, and SSRI use improves depression symptoms in other
patient populations and is safe in CVD patient populations, health care providers should not
hesitate to screen and refer patients for appropriate depression treatment. Pozuelo et al24
cautioned that SSRIs interact with anticoagulants and bleeding should be monitored closely
in patients with CVD who are taking SSRIs.
Whooley28 argued that although there are controversial findings in this area, depression
screening provided in conjunction with collaborative care depression management17,31 is
cost-effective and has a documented positive impact on depression, if not on CVD
outcomes. Whooley noted that there are some costs to screening (eg, false-positive findings,
resulting in stigma for patients incorrectly diagnosed; diversion of health care resources
from other health care needs). However, Whooley suggested that primary care providers,
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rather than cardiologists, should conduct depression screening, and patients should undergo
screening only when an established collaborative care treatment protocol exists.
Carney and others23 argued that depression, like age, clearly marks CVD risk, and health
care providers should treat aggressively the readily modifiable CVD risk factors. In addition,
because of the strong association between depression and medication nonadherence,32
health care providers should carefully monitor patient adherence to life-saving therapies.
Taking another tack, Shemesh and others25 thought it would be important to document the
prevalence of suicidal ideation and intent if the recommendation to screen depression in
CVD patient populations were implemented. In a sample of over 1000 patients with CVD,
they determined the prevalence of suicidal ideation (12.0%) and the number of patients who
required hospitalization for risk of suicide (0.5%) when routine depression screening
occurred in a large cardiology clinic. They concluded that discovery and stabilization of
imminently suicidal patients would be a benefit of universal screening and that there is a
high societal cost to neglecting suicidal ideation, intent, and risk in patients with CVD.
However, more patients would need immediate thorough psychiatric evaluations for safety,
which would affect resource allocation and cost in cardiology clinics.
Arguments Against Depression Screening, Referral, and Treatment in
Patients With CVD
The main argument against screening for and treating depression in patients with CVD was
this: there are neither randomized controlled trials nor systematic evidence-based reviews
showing that screening for depression or screening for depression and referring for
additional treatment sufficiently improves outcomes for depression or CVD, and the existing
evidence does not support the recommendation to screen all patients with CVD.22,30
Furthermore, antidepressant use is associated with only mild improvement in depression
symptoms, even in other patient populations,33 and there have been publication bias (also
known as the file-drawer problem) preventing the publication of antidepressant trials with
null results.34 In addition, considerable health care resources would be required to mount
such a large screening effort, and this resource allocation would be at the expense of other
efforts. Finally, the adverse effects of medications and false-positive results to less-than-
perfect screening must be weighed against any benefit that might occur with universal
screening.35
In addition to the arguments listed above, Ziegelstein and others,29 in commenting on the
American Heart Association advisory21 made the wry observation that there is far greater
observational evidence that depressed patients seen in mental health settings are at risk for
CVD incidence and recurrence and that there should be universal screening and referral for
CVD in patients with depression. They again contended that the evidence is insufficient to
recommend that patients with CVD undergo universal depression screening and referral.
Summary and Clinical Implications for Depression Screening, Referral, and
Treatment in Patients With CVD
Although we were initially hesitant to raise this tense and frequently emotional issue, we are
in favor of routine, algorithm-based depression screening by all cardiologists, with the
following critical proviso: a nationwide and/or Centers for Medicare & Medicaid Studies–
based or randomized controlled trial should be designed and in place. All patients with
pronounced depressive symptoms should be referred to the trial, and 2 depression treatments
should be tested, such as usual referral vs telephone-based collaborative17 or enhanced
depression care.20 In doing so, we can ensure that data are collected on the cost,36 the
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benefit, and even the possible harms associated with recommending depression screening
for patients with CVD, and we can ascertain if there is an acceptable, beneficial treatment
for depression that can be delivered and definitively tested.
Key Findings and Controversies
1. In surprising findings, antidepressant use was associated with increased risk of
incident stroke, CVD, and sudden cardiac death in multiple large observational
cohort studies. It is not known if unmeasured confounders or depressive
symptom severity causes the association, although in some studies controlling
for symptom severity did not decrease this elevated risk. Another interesting
possibility is that the treatment-resistant depressed patient is at particularly high
risk of CVD and mortality.
2. Four exciting randomized controlled trials on depression intervention reported
important efficacy results and suggested future directions for larger, definitive
trials of depression treatment for patients with CVD.
3. A current hotly debated topic is whether patients with CVD should be routinely
screened and subsequently treated for depression. Less controversial, and so less
discussed, is the important insight that psychiatric patients with depression
should be routinely screened for cardiac disease and risk factors, as they are
clearly at risk of CVD; we await clinical trials in this area to ensure that
screening leads to improved CVD outcomes.
4. In the absence of large, randomized controlled trials, the debate continues on
whether depression screening or any type of depression treatment is beneficial,
harmless, or harmful to patients. This debate does not serve patients' or the
public's health and well-being. Researchers, clinicians, and policy makers must
and should resolve to initiate these desperately needed trials.
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